Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study
CONCLUSION: DRd is associated with a significantly lower risk of disease progression or death compared to VRd as 1L treatment for TIE NDMM patients.PMID:37838502 | DOI:10.1016/j.clml.2023.09.003 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 14, 2023 Category: Cancer & Oncology Authors: Lucio Navarro Gordan Carlyn Rose Tan Robert Vescio Jing Christine Ye Carolina Schinke Rohan Medhekar Alex Z Fu Marie-H élène Lafeuille Philippe Thompson-Leduc Vipin Khare John Reitan Gary Milkovich Shuchita Kaila Faith Davies Saad Z Usmani Source Type: research
Current Approach in the Management of Secondary Immunodeficiency in Patients with Hematological Malignancies: Spanish Expert Consensus Recommendations
J Clin Med. 2023 Oct 4;12(19):6356. doi: 10.3390/jcm12196356.ABSTRACTA Delphi-based survey was designed to assess the opinions of clinical hematologists (n = 17) and clinical immunologists (n = 18) from across Spain on secondary immunodeficiencies (SID) in the management of oncohematological patients. There was 100% agreement on the need to have available guidelines for the management of immunodeficiency in hematological patients; to perform a baseline immunological evaluation in patients with chronic lymphocytic leukemia (CLL), multiple myeloma (MM), lymphoma and hematopoietic stem cell transplantation (HSCT) recipients; ...
Source: Clinical Lymphoma and Myeloma - October 14, 2023 Category: Cancer & Oncology Authors: Concepci ón Boqué Silvia S ánchez-Ramón Ra úl Córdoba Carol Moreno Elena Cabezudo Source Type: research
Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study
CONCLUSION: DRd is associated with a significantly lower risk of disease progression or death compared to VRd as 1L treatment for TIE NDMM patients.PMID:37838502 | DOI:10.1016/j.clml.2023.09.003 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 14, 2023 Category: Cancer & Oncology Authors: Lucio Navarro Gordan Carlyn Rose Tan Robert Vescio Jing Christine Ye Carolina Schinke Rohan Medhekar Alex Z Fu Marie-H élène Lafeuille Philippe Thompson-Leduc Vipin Khare John Reitan Gary Milkovich Shuchita Kaila Faith Davies Saad Z Usmani Source Type: research
Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL
CONCLUSIONS: Our findings suggest that both pretreatment and D30 MTV are predictive of outcomes among R/R B-NHL patients treated with CAR T-cell therapy. These data indicate that efforts to reduce pretreatment tumor burden may improve longitudinal clinical outcomes. Furthermore, D30 postinfusion MTV quantification may aid clinicians in optimally identifying patients at high-risk for progression, and in whom closer disease monitoring should be considered. MTV also adds prognostic value to patients with high-risk IPI and holds promise for incorporation in novel risk scoring systems which can identify patients prior to CAR T-...
Source: Clinical Lymphoma and Myeloma - October 12, 2023 Category: Cancer & Oncology Authors: Alexandra E Rojek Justin P Kline Nicholas Feinberg Daniel E Appelbaum Yonglin Pu Benjamin A Derman Andrzej Jakubowiak Satyajit Kosuri Hongtao Liu Mariam T Nawas Sonali M Smith Michael R Bishop Peter A Riedell Source Type: research
Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL
CONCLUSIONS: Our findings suggest that both pretreatment and D30 MTV are predictive of outcomes among R/R B-NHL patients treated with CAR T-cell therapy. These data indicate that efforts to reduce pretreatment tumor burden may improve longitudinal clinical outcomes. Furthermore, D30 postinfusion MTV quantification may aid clinicians in optimally identifying patients at high-risk for progression, and in whom closer disease monitoring should be considered. MTV also adds prognostic value to patients with high-risk IPI and holds promise for incorporation in novel risk scoring systems which can identify patients prior to CAR T-...
Source: Clinical Lymphoma and Myeloma - October 12, 2023 Category: Cancer & Oncology Authors: Alexandra E Rojek Justin P Kline Nicholas Feinberg Daniel E Appelbaum Yonglin Pu Benjamin A Derman Andrzej Jakubowiak Satyajit Kosuri Hongtao Liu Mariam T Nawas Sonali M Smith Michael R Bishop Peter A Riedell Source Type: research
Evaluating Response Trends of Chlormethine/Mechlorethamine Gel in Patients With Stage I-IIA Mycosis Fungoides: Analysis of Individual Patient Data From a Randomized Controlled Phase II Study to Facilitate Optimal Treatment Experiences
CONCLUSIONS: Results presented here can facilitate optimal treatment experiences for patients starting CL gel.PMID:37802679 | DOI:10.1016/j.clml.2023.08.020 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 6, 2023 Category: Cancer & Oncology Authors: Larisa J Geskin James T Angello Martine Bagot Emmanuella Guenova Neda Nikbakht Christiane Querfeld Julia J Scarisbrick Source Type: research
Evaluating Response Trends of Chlormethine/Mechlorethamine Gel in Patients With Stage I-IIA Mycosis Fungoides: Analysis of Individual Patient Data From a Randomized Controlled Phase II Study to Facilitate Optimal Treatment Experiences
CONCLUSIONS: Results presented here can facilitate optimal treatment experiences for patients starting CL gel.PMID:37802679 | DOI:10.1016/j.clml.2023.08.020 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 6, 2023 Category: Cancer & Oncology Authors: Larisa J Geskin James T Angello Martine Bagot Emmanuella Guenova Neda Nikbakht Christiane Querfeld Julia J Scarisbrick Source Type: research
Evaluating Response Trends of Chlormethine/Mechlorethamine Gel in Patients With Stage I-IIA Mycosis Fungoides: Analysis of Individual Patient Data From a Randomized Controlled Phase II Study to Facilitate Optimal Treatment Experiences
CONCLUSIONS: Results presented here can facilitate optimal treatment experiences for patients starting CL gel.PMID:37802679 | DOI:10.1016/j.clml.2023.08.020 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 6, 2023 Category: Cancer & Oncology Authors: Larisa J Geskin James T Angello Martine Bagot Emmanuella Guenova Neda Nikbakht Christiane Querfeld Julia J Scarisbrick Source Type: research
Evaluating Response Trends of Chlormethine/Mechlorethamine Gel in Patients With Stage I-IIA Mycosis Fungoides: Analysis of Individual Patient Data From a Randomized Controlled Phase II Study to Facilitate Optimal Treatment Experiences
CONCLUSIONS: Results presented here can facilitate optimal treatment experiences for patients starting CL gel.PMID:37802679 | DOI:10.1016/j.clml.2023.08.020 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 6, 2023 Category: Cancer & Oncology Authors: Larisa J Geskin James T Angello Martine Bagot Emmanuella Guenova Neda Nikbakht Christiane Querfeld Julia J Scarisbrick Source Type: research
Evaluating Response Trends of Chlormethine/Mechlorethamine Gel in Patients With Stage I-IIA Mycosis Fungoides: Analysis of Individual Patient Data From a Randomized Controlled Phase II Study to Facilitate Optimal Treatment Experiences
CONCLUSIONS: Results presented here can facilitate optimal treatment experiences for patients starting CL gel.PMID:37802679 | DOI:10.1016/j.clml.2023.08.020 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 6, 2023 Category: Cancer & Oncology Authors: Larisa J Geskin James T Angello Martine Bagot Emmanuella Guenova Neda Nikbakht Christiane Querfeld Julia J Scarisbrick Source Type: research
Evaluating Response Trends of Chlormethine/Mechlorethamine Gel in Patients With Stage I-IIA Mycosis Fungoides: Analysis of Individual Patient Data From a Randomized Controlled Phase II Study to Facilitate Optimal Treatment Experiences
CONCLUSIONS: Results presented here can facilitate optimal treatment experiences for patients starting CL gel.PMID:37802679 | DOI:10.1016/j.clml.2023.08.020 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 6, 2023 Category: Cancer & Oncology Authors: Larisa J Geskin James T Angello Martine Bagot Emmanuella Guenova Neda Nikbakht Christiane Querfeld Julia J Scarisbrick Source Type: research
Creating Equitable and Inclusive Clinical Trials for Multiple Myeloma
Clin Lymphoma Myeloma Leuk. 2023 Sep 15:S2152-2650(23)01551-3. doi: 10.1016/j.clml.2023.09.004. Online ahead of print.ABSTRACTBlack and Latino/Hispanic populations are disproportionately impacted by multiple myeloma (MM) in the United States and are underrepresented in many clinical trials. The Multiple Myeloma Research Foundation sponsored a 1-day workshop of 46 experts spanning the ecosystem of MM research and care, including government, academia, nonprofits, pharma/biotech, community partners, and retail pharmacy. Specific, tangible steps to overcome the well-documented barriers to improving the diversity and inclusivit...
Source: Clinical Lymphoma and Myeloma - October 2, 2023 Category: Cancer & Oncology Authors: Monique Hartley-Brown Craig E Cole Pamela Price Michael Andreini George Mulligan Anne Quinn Young Hearn Jay Cho Source Type: research
Creating Equitable and Inclusive Clinical Trials for Multiple Myeloma
Clin Lymphoma Myeloma Leuk. 2023 Sep 15:S2152-2650(23)01551-3. doi: 10.1016/j.clml.2023.09.004. Online ahead of print.ABSTRACTBlack and Latino/Hispanic populations are disproportionately impacted by multiple myeloma (MM) in the United States and are underrepresented in many clinical trials. The Multiple Myeloma Research Foundation sponsored a 1-day workshop of 46 experts spanning the ecosystem of MM research and care, including government, academia, nonprofits, pharma/biotech, community partners, and retail pharmacy. Specific, tangible steps to overcome the well-documented barriers to improving the diversity and inclusivit...
Source: Clinical Lymphoma and Myeloma - October 2, 2023 Category: Cancer & Oncology Authors: Monique Hartley-Brown Craig E Cole Pamela Price Michael Andreini George Mulligan Anne Quinn Young Hearn Jay Cho Source Type: research
Creating Equitable and Inclusive Clinical Trials for Multiple Myeloma
Clin Lymphoma Myeloma Leuk. 2023 Sep 15:S2152-2650(23)01551-3. doi: 10.1016/j.clml.2023.09.004. Online ahead of print.ABSTRACTBlack and Latino/Hispanic populations are disproportionately impacted by multiple myeloma (MM) in the United States and are underrepresented in many clinical trials. The Multiple Myeloma Research Foundation sponsored a 1-day workshop of 46 experts spanning the ecosystem of MM research and care, including government, academia, nonprofits, pharma/biotech, community partners, and retail pharmacy. Specific, tangible steps to overcome the well-documented barriers to improving the diversity and inclusivit...
Source: Clinical Lymphoma and Myeloma - October 2, 2023 Category: Cancer & Oncology Authors: Monique Hartley-Brown Craig E Cole Pamela Price Michael Andreini George Mulligan Anne Quinn Young Hearn Jay Cho Source Type: research
Significance of alkaline Phosphatase After Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma
CONCLUSIONS: Our results suggest that the ALP levels after CAR-T therapy could serve as a suitable biomarker for monitoring CAR-T cell proliferation, CRS grading, and prognosis in patients with MM.PMID:37777383 | DOI:10.1016/j.clml.2023.08.017 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 30, 2023 Category: Cancer & Oncology Authors: Rujiao Dong Yudi Wang Xiaohong Sun Yuanyuan Lin Yuqing Luo Chongyun Xing Lan Sun Shenghui Zhang Kang Yu Songfu Jiang Yi Chen Source Type: research
